Ascendis Pharma Current Ratio 2015-2021 | ASND

Current and historical current ratio for Ascendis Pharma (ASND) from 2015 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations. Ascendis Pharma current ratio for the three months ending June 30, 2021 was 8.31.
Ascendis Pharma Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $0.70B $0.09B 8.31
2021-03-31 $0.83B $0.09B 9.42
2020-12-31 $0.85B $0.06B 14.02
2020-09-30 $1.12B $0.08B 14.80
2020-06-30 $0.54B $0.06B 9.04
2020-03-31 $0.61B $0.05B 13.19
2019-12-31 $0.69B $0.05B 12.74
2019-09-30 $0.75B $0.05B 15.75
2019-06-30 $0.79B $0.07B 11.59
2019-03-31 $0.81B $0.04B 22.32
2018-12-31 $0.35B $0.05B 7.53
2018-09-30 $0.38B $0.04B 10.54
2018-06-30 $0.43B $0.04B 9.87
2018-03-31 $0.44B $0.02B 20.55
2017-12-31 $0.23B $0.03B 8.61
2017-09-30 $0.25B $0.02B 10.85
2017-06-30 $0.15B $0.02B 8.54
2017-03-31 $0.18B $0.02B 9.28
2016-12-31 $0.20B $0.02B 13.67
2016-09-30 $0.09B $0.01B 6.52
2016-06-30 $0.11B $0.01B 8.17
2016-03-31 $0.12B $0.01B 9.90
2015-12-31 $0.14B $0.01B 10.98
2015-09-30 $0.15B $0.01B 14.18
2015-06-30 $0.16B $0.01B 11.49
2015-03-31 $0.18B $0.01B 12.88
2014-12-31 $0.07B $0.02B 4.14
2014-03-31 $0.00B 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $7.881B $0.008B
Ascendis Pharma A/S is a biopharmaceutical company. The company's product pipeline consist of TransCon Human Growth Hormone, TransCon Treprostinil, TransCon Insulin, TransCon Peptide and TransCon Ranibizumab, which are in different clinical stage, for the treatments of hormone deficiency, endocrinology, central nervous system disorders, infectious diseases and diabetes. Its technology includes TransCon which develop prodrug therapies. Ascendis Pharma A/S is based in Denmark.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.416B 8.62
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.526B 21.21
Biohaven Pharmaceutical Holding (BHVN) United States $9.249B 0.00
Emergent Biosolutions (EBS) United States $2.705B 6.53
Arcus Biosciences (RCUS) United States $2.404B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.873B 0.00
Myovant Sciences (MYOV) United Kingdom $1.831B 0.00
Zymeworks (ZYME) Canada $1.080B 0.00
Ambrx Biopharma (AMAM) United States $0.464B 0.00
SQZ Biotechnologies (SQZ) United States $0.372B 0.00
Enzo Biochem (ENZ) United States $0.161B 15.86